Ontology highlight
ABSTRACT:
SUBMITTER: Martner A
PROVIDER: S-EPMC4760300 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Martner Anna A Rydström Anna A Riise Rebecca E RE Aurelius Johan J Anderson Harald H Brune Mats M Foà Robin R Hellstrand Kristoffer K Thorén Fredrik B FB
Oncoimmunology 20150505 1
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cyt ...[more]